...
Why us? Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

Author Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making.

MD MRCGP DFFP
Was this answer helpful?
Authored and medically reviewed by Dr Farzana Khan on 1 September 2026
Rate Dr Farzana's explanation



Barrier biology


UTI cautious


Assessment first

Women’s Health Clinic FAQ

Can regenerative treatment restore Skene's gland antimicrobial secretions?

Barrier-repair language can sound persuasive, but recurrent urinary symptoms still need careful diagnosis.

Direct answer

Skene's gland secretions may contribute to the periurethral environment, but there is not enough patient-facing evidence to promise that regenerative treatment restores antimicrobial fluid secretion or prevents recurrent UTIs. Symptoms around the urethral opening can reflect GSM, dermatitis, infection, urethral pain, pelvic-floor guarding or bladder conditions. The useful clinical route is assessment first, with treatment chosen for the confirmed problem.

The safest page separates confirmed infection from GSM, microbiome disturbance, friction, bladder pain and pelvic-floor symptoms. It explains plausible tissue biology without replacing urine testing, swabs, guideline-based care or clinician judgement.


Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.

Women's Health Clinic consultation about Can regenerative treatment restore Skene's gland antimicrobial secretions?

Microbiome and recurrent UTI

At a glance

These points keep the answer grounded before regenerative treatment, microbiome testing or supplement choices are considered.

At a glance

Clinical summary

Barrier theory is plausible

Hydration, inflammation and tissue integrity may affect comfort.

Infection is specific

Recurrent UTI should be confirmed and tracked with urine results.

Claims need restraint

Tissue repair does not automatically prevent bacterial invasion.

Standard care stays visible

NICE-aligned recurrent-UTI care should not be bypassed.

Important safety note

Fever, flank pain, visible blood in urine, pregnancy, severe pelvic pain, urinary retention, recurrent upper UTI or suspected cancer symptoms should be medically reviewed before elective intimate treatment.

Urothelium
Inflammation
Culture
GSM
Review




Detailed answer

Detailed answer

The useful explanation is urothelial barrier function and local inflammation, while keeping infection diagnosis and evidence limits clear.

The clinical distinction

Recurrent UTI, UTI-like burning, GSM, BV, cytolytic vaginosis, pelvic-floor pain and bladder pain syndrome can overlap. The treatment route should follow the most likely cause, not the most appealing treatment label.

Barrier
Microbiome
Testing
Evidence

What the barrier does

The urethral and bladder lining helps separate urine, microbes and sensitive tissue.

Why fragility matters

GSM, friction and inflammation can make symptoms easier to trigger.

Why proof matters

A regenerative mechanism is not the same as proven recurrent-UTI prevention.

What guides next steps

Culture history, symptom timing and red flags shape the safest plan.

What this means in practice

A plausible biological mechanism does not prove that a regenerative option will reduce infections, restore the microbiome or resolve urinary symptoms.

A safe consultation should review cultures, triggers, GSM symptoms, vaginal symptoms, medicines, pregnancy status, immune risk and red flags.





Patient safety

Why this matters

Recurrent urinary and vaginal symptoms can be exhausting and intimate, but guessing the cause can lead to the wrong treatment.

It protects diagnosis

Culture-positive UTI should be separated from irritation, GSM, BV, bladder pain or pelvic-floor symptoms.

It avoids overclaiming

Regenerative biology may be interesting, but prevention and microbiome claims need cautious evidence language.

It keeps NICE care visible

Vaginal oestrogen, self-care, methenamine and antibiotic decisions may be relevant depending on the case.

It supports confidence

A clear plan may reduce confusion around sex-triggered burning, negative cultures and recurring symptoms.

A better conversation

The goal is not to dismiss regenerative care, but to place it after diagnosis, standard options and evidence counselling.

Patients should leave understanding what is known, what is uncertain, and what would change the plan.





Considerations

What to consider

Before regenerative treatment, the clinical review should clarify infection history, vaginal symptoms, menopause status, medicines, microbiome context, sexual triggers and red flags.

Consultation priorities

The first step is usually history, examination where appropriate, urine or vaginal testing when indicated, and discussion of standard-care options.

Culture
pH
GSM
Review

Testing first

Urine culture, swabs, pH or microbiome testing may be relevant, but the right test depends on symptoms.

Standard options

Discuss vaginal oestrogen, moisturisers, lubricants, self-care, methenamine or antibiotic strategies where appropriate.

Regenerative limits

PRP, polynucleotides, exosomes, laser and RF should be framed as adjunctive or evidence-limited for recurrent UTI claims.

When to delay

Delay elective procedures if infection, unexplained bleeding, severe pain, pregnancy, resistant organisms or systemic illness needs review.

What not to assume

Do not assume a microbiome result, pH reading or tissue treatment explains every episode of burning or urgency.

Follow-up should track symptom pattern, confirmed infections, comfort, recurrence triggers and any adverse changes.





Common concerns and myths

Common misconceptions

These myths are common because recurrent UTI and microbiome marketing often make complex symptoms sound too simple.

Myth: Regenerative injections sterilise the bladder

Reality: recurrent urinary or vaginal symptoms need diagnosis before treatment claims are made.

Myth: Better tissue quality always means fewer UTIs

Reality: microbiome, GSM, infection, tissue fragility and bladder pain can overlap but are not interchangeable.

Myth: Negative cultures mean symptoms are imaginary

Reality: results vary, evidence has limits, and follow-up should guide whether the plan continues or changes.

Biology is not a promise

Glycogen, Lactobacillus, cytokines, vascularity and tissue hydration are useful concepts, but they do not promise fewer infections.

Symptoms need context

A patient can have UTI-like symptoms from GSM, inflammation, pelvic-floor guarding, bladder pain or vaginal infection.





Safety checklist

Safety checklist

Use these checks before considering regenerative urogynaecology treatment for recurrent urinary or microbiome-related symptoms.

Has infection been checked?

Recurrent UTI should be assessed with symptom history and urine testing where clinically indicated.

Has GSM been considered?

Dryness, burning, urgency and recurrent UTI after menopause may relate to low-oestrogen tissue change.

Are vaginal symptoms tested?

Discharge, odour, irritation or recurrent flares may need pH, swabs or microscopy before procedures.

Are expectations realistic?

Adjunctive regenerative care should not be treated as proven infection prevention or a substitute for standard care.

Reassuring signs

Proceeding is more reasonable when infection is excluded or treated, red flags are absent, options are explained and follow-up is planned.

Tested
Explained
Reviewed

Reasons to pause

Pause if there is fever, flank pain, visible blood in urine, urinary retention, pregnancy, severe pelvic pain, active infection or unexplained bleeding.

Fever
Blood
Retention




When to escalate

When to seek medical help

Some recurrent urinary or vaginal symptoms need prompt medical assessment rather than elective regenerative treatment.

Use NHS 111 online

Possible kidney infection

Fever, chills, flank pain, vomiting or feeling very unwell should be assessed urgently.

Blood or retention

Visible blood in urine, inability to pass urine or severe bladder pain needs prompt review.

Pregnancy or complex history

Pregnancy, recurrent upper UTI, immune suppression, kidney disease or resistant organisms should be medically managed.

Emergency symptoms

Call 999 for life-threatening symptoms such as collapse, chest pain, breathing difficulty or sudden neurological symptoms.

Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.

More clinical detail

Why urothelial barrier function and local inflammation needs careful framing

Regenerative urogynaecology sits at the edge of tissue biology, symptom care and evidence uncertainty. The useful patient question is not whether a pathway sounds regenerative, but whether the symptom has been correctly identified.

What patients can safely ask

Ask whether symptoms are culture-positive infection, GSM, vaginal dysbiosis, friction, bladder pain or pelvic-floor related; what tests are needed; what standard options apply; and what evidence supports any adjunctive treatment.

What should stay clinician-led

Antibiotic decisions, methenamine decisions, oestrogen suitability, injectable technique, laser or RF technical choices, microbiome interpretation and treatment timing should be handled through clinical assessment and consent.

Next step

Book a specialist consultation

A consultation can review recurrent urinary symptoms, GSM, vaginal symptoms, test results and whether standard or adjunctive treatment options are appropriate.

View Research Sources (12 Sources)
• NICE NG112 recurrent urinary tract infection antimicrobial prescribing
• NICE NG23 menopause recommendations
• BAUS cystitis and recurrent UTIs
• EAU urological infections recurrent UTI summary
• GMC decision making and consent
• NIHR Be Part of Research CO2 laser recurrent UTI trial
• Serenity Women's Clinic NewGyn polynucleotides for intimate areas
• Meyer Clinic vaginal health
• Tota vaginal and urine microbiome test
• Jennifer Derham recurrent UTI treatment London
• British Menopause Society genitourinary syndrome of menopause
• Clinical literature on GSM, Lactobacillus, vaginal pH and recurrent UTI

These 12 source names are selected from 107 curated sources. Additional reviewed material included professional society guidance, peer-reviewed clinical papers, evidence reviews, clinical trial records; duplicate and low-relevance records were removed before display.

Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.

  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • Non-NHS: Private healthcare provider only. Pricing varies by treatment and site. Availability varies by clinical location.